A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Trial Profile

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs INCB 50465 (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms CITADEL-202
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 In a planned interim futility analysis of Group A, the study will be terminated if less than or equal to 13 of the first 40 treated pts respond (no futility analysis of Group B will be conducted) as per trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 22 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top